arrow
P

Peter Rohloff

Harvard University
H指数:43
被引数:2.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Ethical Considerations for Research in CKD of Unknown Etiology: Reflections From an Ethics Panel at the Fourth International Workshop on CKD of Unknown Etiology

CKD病因不明研究的伦理考量:第四届不明原因CKD国际研讨会伦理委员会的反思

2025-07-050
OAAI
Rationale and Design of the International Prospective Study of CKD of Uncertain Etiology in Agricultural Communities

国际农业社区不明原因慢性肾脏病前瞻性研究的理由与设计

2025-06-300
OAAI
Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults

2022年1990年体重不足和肥胖的全球趋势: 对2.22亿名儿童、青少年和成人的3663项人口代表性研究的汇总分析

LANCET
IF88.5
2024-03-01296
OAAI
Global Prevalence of Aspirin Use for Primary Prevention of Cardiovascular Disease: A Cross-Sectional Study of Nationally Representative, Individual-Level Data

阿司匹林用于心血管疾病一级预防的全球患病率: 一项具有全国代表性的个人水平数据的横断面研究

2024-01-011
OAAI
Global variation in diabetes diagnosis and prevalence based on fasting glucose and hemoglobin A1c

基于空腹血糖和血红蛋白A1c的糖尿病诊断和患病率的全球差异

2023-11-0923
OAAI
Aspirin for Secondary Prevention of Cardiovascular Disease in 51 Low-, Middle-, and High-Income Countries

阿司匹林用于51个低、中、高收入国家的心血管疾病二级预防

2023-08-228
OA
Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021

全球、区域和国家糖尿病负担1990年2021年,以及患病率2050年预测: 全球疾病负担研究的系统分析2021

LANCET
IF88.5
2023-07-01941
OAAI